or
Bookmark and Share
Diphenylpropanamines, compositions thereof and use thereof
   
Document Number
US Patent 4364954
Issued Date
December 21, 1982
Link
Inventors
Map
Abstract
Compounds of the formula ##STR1## where X and Y are hydrogen, halogen, lower alkyl, nitro are useful as neuroleptics.
Drawing
Diphenylpropanamines, compositions thereof and use thereof - US Patent 4364954 Drawing
Drawing from US Patent 4364954
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
10
Comments:
no comments yet
Owner
Warner-Lambert Company (Morris Plains, NJ)
Published
December 21, 1982
Application Number
06/268,502
Filed
May 29, 1981
US Classification
514/322   514/338 544/253 544/392 544/394 544/398 544/402 546/112 546/19 546/199 546/20 546/216 546/217 546/223 546/229 546/273.7 546/290 546/297 546/300
Int'l Classification
C07D   211/00   (20060101)   C07D   211/70   (20060101)   C07D   211/52   (20060101)   C07D   241/44   (20060101)   C07D   241/00   (20060101)   C07D   211/74   (20060101)   C07D   211/76   (20060101)   C07D   491/10   (20060101)   C07D   491/00   (20060101)   C07D   453/00   (20060101)   C07D   453/06   (20060101)   C07D   471/00   (20060101)   C07D   471/10   (20060101)  
Examiner
Attorney/Law Firm
Parent Case
This is a division of application Ser. No. 111,043, filed Jan. 10, 1980, now U.S. Pat. No. 4,292,321 which is in turn a continuation of application Ser. No. 042,175 filed May 24, 1979, abandoned.
USPTO Field of Search
546/199   546/271   424/267   424/263  
Related Patents
4411904 - Diphenylpropanamines, compositions thereof and use thereof - Owned by Warner-Lambert Company (Morris Plains, NJ)

Compounds of the formula ##STR1## where X and Y are hydrogen, halogen, lower alkyl, nitro are useful as neuroleptics.

5310902 - Alkylenediamine derivatives - Owned by Nippon Chemiphar Co., Ltd. (Tokyo,JP)

Novel alkylenediamine derivatives effectively employable glutamate blockers have the formula (I) or (II): ##STR1## wherein each of R.sup.1 and R.sup.6 is an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aryl group, or an aralkyl group; each of R.sup.2 and R.sup.7 is an aliphatic hydrocarbon group, an alkoxy group, an aliphatic hydrocarbon group containing an ester bonding, an aliphatic hydrocarbon group containing an ether bonding, or an aryloxy group; each of R.sup.3, R.sup.4, R.sup.5 R.sup.8, R.sup.9 and R.sup.10 is hydrogen, an alkyl group, an alkoxy group, an acyloxy group, an aryl group, an aralkyl group, hydroxyl, a hydroxylalkyl group, halogen, nitrile, nitro, amino, carbamoyl or alkoxycarbonyl; and each of m and n is an integer of 0-3 (m+n does not exceed 3); k is an integer of 1-4; each of p and i is an integer of 2-13; and each of q and j is an integer of 4-7.

6235730 - 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same - Owned by Japan Tobacco, Inc. (Tokyo,JP)

3-piperidyl-4-oxoquinazoline derivatives are provided, which is represented by the formula (I): ##STR1## wherein R represents an amino group or a cyclic amino group such as dibenzoazepine, each of which is substituted with a substituted or unsubstituted aryl group, a substituted or unsubstituted heteroaryl group, or the like, n is an integer of 1 to 3, R.sub.3 and R.sub.4 independently represents a hydrogen atom, a lower alkyl group, or the like, or a pharmaceutically acceptable salt thereof. Compounds (I) of the present invention have excellent MTP-inhibitory activity. Thus, these compounds not only inhibit formation of LDL that is a cause of arteriosclerotic diseases but also regulate TG, cholesterol, and lipoproteins such as LDL in the blood and regulate cellular lipids through regulation of MTP activity. They can also be used as a new type of preventive or therapeutic agents for hyperlipemia or arteriosclerotic diseases. Furthermore, they can be used as therapeutic or preventive agents for pancreatitis, obesity, hypercholesterolemia, and hypertriglyceridemia.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us